HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

VB4-845, a conjugated recombinant antibody and immunotoxin for head and neck cancer and bladder cancer.

Abstract
Viventia Biotech Inc, under license from the University of Zurich, is developing VB4-845, comprising a Pseudomonas exotoxin fused to an anti-epithelial cell adhesion molecule single-chain antibody fragment, for the potential treatment of head and neck cancer (intratumoral) and bladder cancer (intravesical). VB4-845 is currently undergoing phase II and III clinical trials in patients with head and neck squamous cell carcinomas, as well as phase II clinical trials for the treatment of superficial transitional cell carcinoma of the bladder.
AuthorsKristen Biggers, Noah Scheinfeld
JournalCurrent opinion in molecular therapeutics (Curr Opin Mol Ther) Vol. 10 Issue 2 Pg. 176-86 (Apr 2008) ISSN: 1464-8431 [Print] England
PMID18386230 (Publication Type: Journal Article)
Chemical References
  • Antibodies
  • Antineoplastic Agents
  • Immunotoxins
  • Recombinant Proteins
Topics
  • Antibodies (metabolism, therapeutic use)
  • Antineoplastic Agents (metabolism, pharmacokinetics, therapeutic use)
  • Drug Evaluation, Preclinical
  • Head and Neck Neoplasms (drug therapy)
  • Humans
  • Immunotoxins (metabolism, pharmacokinetics, therapeutic use)
  • Recombinant Proteins (therapeutic use)
  • Structure-Activity Relationship
  • Urinary Bladder Neoplasms (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: